Zevra Therapeutics, Inc. (ZVRA) Misses Q3 EPS by 10c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts ZVRA Hot Sheet
Join SI Premium – FREE
Zevra Therapeutics, Inc. (NASDAQ: ZVRA) reported Q3 EPS of ($0.40), $0.10 worse than the analyst estimate of ($0.30). Revenue for the quarter came in at $2.89 million versus the consensus estimate of $3.38 million.
For earnings history and earnings-related data on Zevra Therapeutics, Inc. (ZVRA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Zevra Therapeutics, Inc. (ZVRA) Tops Q3 EPS by 10c
- Vistra stock sinks ahead of earnings report
- Twilio (TWLO) PT Raised to $320 at Tigress Financial Partners
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
